( November 6, 2026, 9:21 AM EST) -- OAKLAND, Calif. — A federal judge in California gave final approval to a $69 million settlement that ends a securities fraud class action brought by investors alleging that a biopharmaceutical company and its CEO made false statements about the safety, efficacy and application for U.S. Food and Drug Administration approval of its proprietary vasculitis drug....